Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer
Interventions: DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Weekly Paclitaxel|DRUG: Trastuzumab|DRUG: Pertuzumab|DIAGNOSTIC_TEST: Celcuity CELx HSF
Sponsor: NSABP Foundation Inc
Collaborators: Celcuity, LLC|Genentech, Inc.